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Abstract
Although the incidence of gastric cancer (GC) has declined steadily in recent years, GC 
remains a major cancer burden. Multimodal therapies have been developed and first-line 
chemotherapy for advanced GC patients, even they have good performance status, could 
provide only modest efficacy. Furthermore, treatment outcomes after failure of first-line 
chemotherapy remain poor. In order to provide a solution to this unmet clinical need, since 
the management of various types of cancer has progressed rapidly into the molecular era, 
biomarker-targeted therapy for GC has received enormous attention in recent years. This 
review focuses on the current treatment achievement of molecular targeting agents for GC, 
such as trastuzumab, pertuzumab, trastuzumab emtansine, lapatinib, cetuximab, panitu-
mumab, nimotuzumab, mammalian target of rapamycin, bevacizumab, ramucirumab, 
sunitinib, sorafenib, apatinib, rilotumumab, and onartuzumab. However, problems are 
also emerged with regard to resistance and refractoriness. This chapter also focuses on the 
current obstacles concerning resistance and refractoriness, as well as provides discussions 
concerning future directions with regard to molecular categorization to predict response 
and toxicities leading to select patients most likely to benefit.
Keywords: gastric cancer, molecular targeting therapy, human epidermal growth factor 
receptors, angiogenesis, resistance
1. Introduction
Although the incidence of gastric cancer (GC) has declined steadily in recent years, GC 
remains a major cancer burden. GC is still the fifth most common malignancy and third lead-
ing cause of cancer death in both sexes worldwide, comprising 8.8% of total cancer deaths 
[1]. Radical resection is the only potentially curative approach for GC; however, approxi-
mately 40–70% of GC recurs even after curative resection [2]. When the disease reaches an 
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advanced state, chemotherapy becomes a mainstay of the treatment [3]. The most frequently 
used first-line chemotherapy regimens worldwide are platinum derivatives plus fluoropy-
rimidine doublet or a triplet regimen with the addition of epirubicin or docetaxel. The reality 
is that chemotherapy has reached a plateau of efficacy for GC with a median overall survival 
(mOS) of around or less than 12 months [4, 5]. Furthermore, although second-line treatment 
is recommended for the patients with failure after first-line chemotherapy because it prolongs 
survival as compared with the best supportive care [6–8], the global standard regimens of 
second-line chemotherapy have not yet been determined [4].
These somewhat painfully slow rates of advances in treatment have been impetus to develop 
new concepts of strategies. As an example, receptor tyrosine kinases (RTKs) consist of the 
ligand binding of extracellular domains, a transmembrane domain, and a tyrosine kinase 
motif, which is involved in a subsequent downstream signal cascade. Since this cascade leads 
to cell growth, differentiation, adhesion, migration, and apoptosis [9], each step is theoreti-
cally a therapeutic target. This review focuses on advances in molecular targeted therapy for 
GC in recent years, as well as problems to be resolved.
2. Focus on human epidermal growth factor receptors (HERs)
Membrane-bound human epidermal growth factor receptors (HERs) consist of a ligand-bind-
ing domain at the extracellular surface, a single transmembrane segment, and a cytoplas-
mic portion harboring the protein kinase activity. The HER family includes four structurally 
related members, namely the epidermal growth factor receptor (EGFR, also known as HER1), 
HER2, HER3, and HER4. Ligand binding to the extracellular domain triggers conformational 
changes of receptors that form HER-dimerization, and subsequently, activates downstream a 
signaling cascade and ultimately stimulates tumor cell proliferation. Therefore, HERs are the 
most innovative targets for GC treatment.
2.1. Trastuzumab
HER2 is responsible for GC cell growth when overexpressed [10]. A literature review dem-
onstrates that the mean incidence of HER2-positive gastric cancer is 18%, ranging from 4 to 
53% [11], and the most recent research confirmed that the HER2 positivity rate to be 21% 
among Japanese patients [12]. A systematic analysis demonstrated the potential role for 
HER2 as a negative prognostic factor [11]; thus, it has become a rational therapeutic target. 
Trastuzumab, a humanized monoclonal antibody that targets the extracellular domain IV 
of the HER2, was evaluated by the first landmark randomized controlled trial (RCT) (ToGA 
trial) [M]. The ToGA trial provided evidence of a significant improvement by the addition 
of trastuzumab to chemotherapy as compared with chemotherapy alone as a first-line set-
ting. In patients with HER2-positive GC, while trastuzumab could achieve longer mOS, a 
higher response rate (RR), and a longer median progression free survival (mPFS) (Table 1), 
toxicity did not differ between groups. A post-hoc analysis revealed that the survival differ-
ences between groups were more evident in patients with immunohistochemistry (IHC)  2+ 
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Reference Publi- 
cation  
year
Design Phase Experimental arm Control arm RR mPFS mOS Study  
name
Agents n Agents n Experi- 
mental  
arm
Control 
arm
p Experi- 
mental  
arm
Control 
arm
p Experi- 
mental  
arm
Control 
arm
p
[13] 2010 1st III F, Cis, T 294 F, Cis 290 47% 35% 0.0017 6.7 5.5 0.0002 13.8 11.1 0.0046 ToGA
[36] Ongoing 1st III T, F, Cis, 
Per
NA T, F, Cis ND ND ND ND ND ND ND ND ND ND JACOB  
(NCT01 
774786)
[37] 2016 2nd II/III T-DM1 228 TAX 117 21% 20% ND 2.7 2.9 NS 7.9 8.6 NS GATSBY 
(NCT016 
41939)
[39] 2015 1st III Cape, Ox, L 249 Cape, Ox 238 53% 39% 0.0031 6 5.4 0.04 12.2 10.5 NS LoGiC
[40] 2014 2nd III PTX, L 132 PTX 129 27% 9% <0.001 5.4 4.4 NS 11 8.9 NS TyTAN
[41] 2013 1st III Cape, Cis, 
Cet
455 Cape, Cis 449 30% 29% NS 4.4 5.6 NS 9.4 10.7 NS EXPAND
[42] 2010 1st III EOC, Pani 278 EOC 275 42% 46% NS 7.4 6 NS 8.8 11.3 0.013 REAL-3
[43] 2015 1st rII S1, Cis, 
Nimo
31 S1, Cis 31 55% 58% NS 7.2 4.8 0.011 14.2 10.2 0.06
[44] 2015 2nd rII Iri, Nimo 40 Iri 43 18% 10% NS 73d 85d NS 251d 232d NS
[50] 2013 2nd or 
further
III Eve 439 – 217 4 2 ND 1.7 1.4 <0.001 5.3 4.3 NS GRANITE-1
[56] 2011 1st III Cape, Cis, 
Bev
387 Cape, Cis 387 46% 37% 0.03 6.7 5.3 0.0037 12.1 10.1 NS AVAGAST
[57] 2015 1st III Cape, Cis, 
Bev
102 Cape, Cis 100 41% 34% NS 6.3 6 NS 10.5 11.4 NS AVATAR
[62] 2014 2nd III Ram 238 – 117 3% 3% NS 2.1 1.3 <0.0001 5.2 3.8 0.047 REGARD
[63] 2014 2nd III PTX, Ram 330 PTX 335 28% 16% 0.0001 4.4 2.9 <0.0001 9.6 7.4 0.017 RAINBOW
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Design Phase Experimental arm Control arm RR mPFS mOS Study  
name
Agents n Agents n Experi- 
mental  
arm
Control 
arm
p Experi- 
mental  
arm
Control 
arm
p Experi- 
mental  
arm
Control 
arm
p
[65] Ongoing 1st III F, Cis, Ram NA F, Cis NA ND ND ND ND ND ND ND ND ND RAINFALL 
(NCT02 
314177)
[66] 2014 1st rII FOLFOX, 
Ram
84 FOLFOX 84 45 46 ND 6.4 6.7 ND 11.7 11.5 ND
[67] 2014 3rd III Apatinib 176 – 91 2.8 0 NS 2.6 1.8 <0.001 6.5 4.7 0.0149
[73] 2016 2nd or 
further
rII FOLFILI, 
sunitinib
45 FOLFILI 45 20 29 ND 3.5 3.3 NS 10.4 8.9 NS
[87] 2015 1st III E, Cis,  
Cape,  
rilotum- 
umab
304 E, Cis, 
Cape
305 30 39 0.027 5.7 5.7 0.016 9.6 11.5 0.016 RILOMET-1 
(NCT016 
97072)
[88] Ongoing 1st III Cis,  
Cape,  
rilotum- 
umab
NA Cis, Cape NA ND ND ND ND ND ND ND ND ND RILOMET-2 
(NCT021 
37343)
[92] 2017 1st III FOLFOX6, 
Ona
279 FOLFOX6 283 46 41 NS 6.7 6.8 NS 11 11.3 NS
RR—response rate; mPFS—median progression free survival; mOS—median overall survival; rII—randomized phase II; NA—not described; NS—not significant; Bev—
bevacizumab; Cape—capecitabine; Cet—cetuximab; Cis—cisplatin; E—epirubicin; EOC—epirubicin, oxaliplatin, capecitabine; Eve—everolimus; F—fluoropyrimidines; 
FOLFIRI—leucovorin + 5-fluorouracil + irinotecan; FOLFOX—leucovorin + 5-fluorouracil + oxaliplatin; Iri—irinotecan; L—lapatinib; Nimo—nimotuzumab; Ona—
onartuzumab; Ox—oxaliplatin; Pani—panitumumab; Per—pertuzumab; PTX—paclitaxel; Ram—ramucirumab; T—trastuzumab; T-DM1—trastuzumab emtansine.
Table 1. Results of phase III or randomized phase II trials of molecular targeting therapy for gastric cancer.
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and fluorescence in situ hybridization (FISH) positive tumors or IHC3+ tumors [13]. The 
ToGA trial also provided evidence of a prolongation of time to the deterioration of health-
related quality of life [14]. Furthermore, the subgroup analyses of the ToGA trial restricted 
to Japanese patients [15] and a subsequent similar phase III study recruiting only Chinese 
patients [16] have confirmed again such promising results, suggesting the efficacy of trastu-
zumab irrespective of country of origin. The results of the ToGA study have changed the 
treatment paradigm for GC harboring HER2 overexpression. Subsequently, a HELOISE 
study has been conducted to investigate the efficacy of different doses of trastuzumab with 
cisplatin and capecitabine [17], resulting in no differences between 6 and 10 mg of trastu-
zumab in terms of mOS and mPFS.
However, targeting HER2 raises important issues that must be discussed, namely, hetero-
geneity and resistance. Heterogeneity should be considered because of a different HER2 
positivity rate according to cancer histology, the location of GC, and geographic area, mak-
ing for various prevalence rates of HER2-positive GC from study to study or from country 
to country. In the ToGA trial discussed above, the HER2 positivity rate was higher in the 
intestinal type (31.8%) than in the diffuse type (6.1%), in specimens from the gastroesopha-
geal junction (32.2%) than in those from the stomach (21.4%), and in patients from Asia-
Pacific (23.9%) or Europe (23.6%) than in patients from Central/South America (16.1%) [18]. 
In addition, one-third of IHC3+ patients had <30% of stained cells, suggesting staining vari-
ability within the same tumor. Furthermore, variations of scoring criteria between studies 
may be another explanation for heterogeneity [11]. Since these variations may undoubtedly 
complicate the interpretation of the results of the clinical trials, there is a need for estab-
lishing a unique scoring system specific for GC [19], which could help identify and select 
HER2-positive patients who benefit from trastuzumab. Another important issue is a trastu-
zumab resistance, which has begun to arise along with the accumulation of experience of 
trastuzumab use. Not all HER2-positive patients immediately benefit from trastuzumab, 
and even those who initially respond to trastuzumab will eventually experience progress, 
suggesting refractories and resistance. In breast cancer, the majority of those who initially 
responded to trastuzumab ultimately became resistant during prolonged treatment [20, 
21]. In looking at the ToGA trial, mPFS was 6.7 months in the trastuzumab arm or the abso-
lute increase in the RR was only 12%, suggesting that half of the GC patients—even though 
they were HER2 positive—exhibit acquired resistance within 7 months or do not necessar-
ily respond to trastuzumab.
When considering the onset of nonresponsiveness to trastuzumab, two statuses should be 
distinguished, namely, resistance and refractoriness. Resistance is a condition of disease pro-
gression at first evaluation even under trastuzumab use, whereas refractoriness is a condition 
of disease progression at second or later evaluations after an initial clinical response [22]. The 
resistance may be ascribed to intrinsic mechanisms, while refractoriness may be related to 
acquired properties. The precise mechanisms of these phenomena are unclear; several path-
ways may be involved, including phosphatidylinositol-3-kinase (PI3K) [23], a mammalian 
target of rapamycin (mTOR) [23], insulin-like growth factor-1 (IGF-1) [24], and a phospha-
tase and tensin homolog (PTEN) [25]. This encourages the development of second-generation 
agents of targeting HER2 to overcome HER2 resistance.
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2.2. Pertuzumab
Pertuzumab is a humanized monoclonal antibody that binds to the HER2 domain II—the 
interface of the dimer formation of HER. As discussed earlier, since trastuzumab binds to 
the HER2 domain IV—a region not involved in receptor dimerization [26, 27], trastuzumab 
inhibits ligand-independent dimerization of HER2 while it is not effective for the inhibition 
of ligand-dependent heterodimerization. These biological properties could imply one mecha-
nism of trastuzumab resistance. For example, HER ligands are able to induce the formation 
of HER2-containing heterodimers such as the ligand-dependent HER2/HER3 heterodimer 
even in the presence of trastuzumab; thus HER3 plays some roles in trastuzumab resistance. 
Notably, HER3 is overexpressed in 14–62% of GC [28–30], and HER3 per se is associated with 
poor survival rates. Considering that pertuzumab binds to the HER2 domain II and subse-
quently blocks the heterodimerization of HER2 with other members of the HER family, per-
tuzumab is expected to overcome trastuzumab resistance.
In in vitro studies and animal models, pertuzumab and trastuzumab showed synergistic anti-
tumor effects [31–33]. Subsequent RCT in HER2-positive metastatic breast cancer demon-
strated that pertuzumab, trastuzumab, and docetaxel significantly improved overall survival 
rates for HER2-positive metastatic breast cancer when compared with placebos, trastuzumab, 
and docetaxel [34]. Such positive results were maintained when the follow-up period was 
extended [35]. Motivated by the promising results, a phase III study is ongoing which ran-
domizes HER2-positive advanced GC patients to first-line trastuzumab, cisplatin, and fluoro-
pyrimidine with or without pertuzumab [36].
2.3. T-DM1
T-DM1 is an antibody drug conjugate of trastuzumab and emtansine (DM1), a microtubule 
inhibitor. TDM-1 is expected to deliver a cytotoxic agent directly to cancer cells. Unfortunately, 
however, the efficacy of T-DM1 as compared to taxane as a second-line setting failed to meet 
its primary endpoint (GATSBY trial). The mOS, mPFS, and RR were not different between the 
two arms [37].
2.4. Lapatinib
Lapatinib is a small molecule inhibitor of the intracellular domain of tyrosine kinase of 
EGFR and HER2, thus interrupting EGFR- and HER2-associated downstream signaling cas-
cades. Theoretically, lapatinib and trastuzumab synergistically act even on the status of 
trastuzumab resistance. Indeed, a meta-analysis has revealed [38] the efficacy of lapatinib 
on HER2-positive breast cancer patients. Accordingly in GC, lapatinib in combination with 
chemotherapy has been evaluated by two randomized trials as first-line [39] and second-
line [40] settings. Unfortunately, the addition of lapatinib to capecitabine plus oxaliplatin 
(LoGiC trial) [39] or the addition of lapatinib to paclitaxel (TyTAN trial) [40] failed to dem-
onstrate any significant improvement of mOS when compared with chemotherapy without 
lapatinib.
However, some confusion may exist when considering clinicopathological subsets that 
receive benefit from agents against HER2. A LoGiC study revealed that Asian or younger 
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(age <60 years old) patients may benefit from lapatinib [39], while a ToGA trial proved trastu-
zumab efficacy to be more effective in patients from Central/South America or from Europe, 
or in older patients [13]. In addition, the TyTAN study, which was conducted only in Asia, 
failed to identify any clear subgroup benefit from lapatinib except for patients from mainland 
China. Therefore, it is important to clarify biomarkers that may predict which patients may 
benefit from dual EGFR/HER2 inhibition.
2.5. Cetuximab, panitumumab, and nimotuzumab
Cetuximab is a recombinant human-mouse chimeric anti-EGFR antibody. A randomized 
EXPAND study as a first-line setting revealed that the addition of cetuximab to capecitabine 
plus cisplatin provided no additional benefit to chemotherapy [41]. Panitumumab is a fully 
humanized anti-HER1 antibody. A REAL-3 study randomized advanced GC patients to first-
line epirubicin, oxaliplatin, and capecitabine with or without panitumumab [42]. Again, pertu-
zumab provided no additional survival benefit to chemotherapy or seemed to be even harmful.
Following by the negative results of the two RCTs (EXPAND and REAL-3), another anti-EGFR 
antibody, nimotuzumab, a recombinant humanized monoclonal antibody against EGFR [43, 
44] has been developed. Regrettably, however, a randomized phase II study adding first-
line nimotuzumab to S-1 plus cisplatin failed to improve mOS when compared to S-1 plus 
cisplatin. In this study, even among the EGFR2+/3+ subgroup, adding nimotuzumab did not 
provide any additional benefit to the S-1 plus cisplatin combination [43]. However, nimo-
tuzumab and irinotecan could improve survival rates in the EGFR2+/3+ subgroup [44]. The 
exact reasons underlying these different results according to the chemotherapy agents com-
bined with nimotuzumab are unclear, but putative mechanisms responsible for the confusing 
results may be negative synergistic effects between the anti-EGFR antibody and capecitabine.
Unlike in colorectal cancer, KRAS mutations have not been a negative predictive marker for 
EGFR-targeting therapy in GC [45], and prespecified KRAS mutations have limited clinical 
value. Therefore, the significance of KRAS gene mutations, which is a predictive factor for a 
lack of efficacy in colorectal cancer, may not be extrapolated to GC, and KRAS mutations are 
not validated at this time. It is possible that alternative mechanisms other than KRAS muta-
tions to escape from cetuximab action may exist. In this regard, attempts to find predictors 
of the efficacy of EGFR-targeting therapies have been reported in Refs. [46–48]; however, a 
small number of patients investigated in such biomarker analyses and a retrospective study 
design may preclude drawing a meaningful conclusion. Furthermore, the very low rate of 
KRAS mutation in GC (3–9%) [46–48] also hinders further application in clinical practice. The 
identification of reliable predictive markers is of paramount importance for selecting the most 
appropriate agents to the patients benefiting most.
2.6. Mammalian target of rapamycin (mTOR)
The mammalian target of rapamycin (mTOR) is one of the key protein kinases that regulate cell 
growth, proliferation, and angiogenesis [49] and is integrated in the downstream cascade of 
HER. The inhibition of mTOR is thus an intriguing new therapeutic approach. Everolimus, an 
oral mTOR inhibitor, did not significantly improve mOS but could reduce the risk of disease 
progression (p < 0.001) when compared with the best supportive care (GRANITE-1 trial) [50].
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3. Anti-antigenic
Angiogenesis was postulated 40 years ago as an essential event for tumors to grow beyond 
a critical size of few millimeters. Except for physiological conditions requiring angiogenesis 
such as embryogenesis and wound healing, inhibiting neovascularization may contribute to 
tumor growth arrest with minimal toxicities to normal tissues. Therefore, targeting molecules 
involved in neovascularization has gained recognition as a rational therapeutic option.
3.1. Bevacizumab
Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF)-A, 
which is effective in combination with chemotherapy in several kinds of malignancies includ-
ing the colon [51], breast [52], and lung [53]. Against the background that the overexpres-
sion of VEGF was correlated with tumor aggressiveness and poor prognosis in GC [54, 55], a 
randomized AVAGAST study was conducted to evaluate the efficacy of adding bevacizumab 
to capecitabine plus cisplatin in the first-line treatment of advanced GC [56]. The results did 
not meet the primary outcome; however, adding bevacizumab to chemotherapy resulted in 
a significant prolongation of mPFS and a significant increase in RR. In the subgroup analysis 
of AVAGAST study, geographical differences in efficacy were suggested, it being effective in 
Pan-America whereas not so in Asia and Europe. Subsequently, an AVATAR trial in which 
the trial design is similar with that of AVAGAST has been conducted for 202 Chinese patients 
with the results recently published [57]. Again, neither mOS nor mPFS were improved by the 
addition of bevacizumab to chemotherapy. Based on the negative results of the two RCTs, 
research should be continued to seek the biomarker predictive for bevacizumab efficacy in 
order to determine the bevacizumab rational position in the treatment of advanced GC [58]. 
Candidates for potential predictive biomarkers include plasma VEGF-A level and tissue neu-
ropilin-1 expression [58]. However, other cancers had potential other predictive markers for 
bevacizumab efficacy, being VEGF-A and VEGFR-2 in breast cancer [59] or VEGFR-1 single-
nucleotide polymorphism in pancreatic and renal cell cancer [60].
3.2. Ramucirumab
Ramucirumab is a fully humanized monoclonal antibody that blocks the binding of VEGF-A, 
C, and D to the extracellular domain of VEGF receptor-2 (VEGFR-2); thus, ramucirumab inhib-
its the ligand activation of a downstream signal transduction of VEGF-R [61]. The REGARD 
trial is the first RCT demonstrating survival benefits for second-line ramucirumab when com-
pared with the best supportive care [62]. Subsequently, the RAINBOW trial was conducted to 
evaluate the second-line efficacy of weekly paclitaxel with or without ramucirumab [63]. The 
subgroup analysis demonstrated that ramucirumab was not effective in Asian patients when 
compared with those from Europe and the USA; however, this geographical difference was 
ascribed partly to the high proportion of patients receiving postdiscontinuation therapy—at 
least for Japanese patients [64]. Currently, ramucirumab has been evaluated as a first-line 
setting in combination with fluoropyrimidines and cisplatin (RAINFALL trial) [65] or in com-
bination with FOLFOX [66].
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3.3. VEGFR tyrosine kinase inhibitors—sunitinib, sorafenib, and apatinib
VEGFR-1, -2, and -3 are RTKs by which a downstream signaling cascade is stimulated to 
induce angiogenesis when corresponding ligands VEGF-A, -B, -C, and -D bind to the recep-
tors. Several small molecules, which block some steps of this cascade, have been developed. 
Apatinib is a small molecule of VEGFR-2 tyrosine kinase inhibitor that has been compared 
with placebos for the second-line treatment of advanced GC. One RCT revealed that apatinib 
achieved significantly prolonged mOS and mPFS when compared with placebos [67]. These 
positive findings by inhibiting VEGFR-2 and its related tyrosine kinases have promoted inter-
est in VEGFR inhibition as a therapeutic strategy.
However, pathways of other growth factors, such as platelet-derived growth factor (PDGF), 
may be responsible for alternative escape mechanisms to the VEGF-VEGFR blockade [68, 69] 
and may be one reason for resistance to antiangiogenic therapy. These findings have prompted 
the development of several small molecules targeting multiple RTKs with expectations to 
overcome an escape from the VEGF-VEGFR blockade. Sorafenib is a multikinase inhibitor 
that targets multiple RTKs such as VEGFR-2, -3, PDGF-receptor (PDGF-R), c-Kit, and Raf 
[70, 71]. Sunitinib is another oral multitarget kinase inhibitor of VEGFR, PDGFR, and the Kit 
receptor [72]. A randomized phase II trial demonstrated a trend toward better mOS in suni-
tinib plus FORFIRI arm as compared with a FOLFIRI arm, whereas PFS and RR were similar 
between both arms [73]. Regorafenib is another oral multikinase inhibitor of receptor tyrosine 
kinases of VEGFR, B-RAF, and PDGFR [74]. A PFS was significantly improved by regorafenib 
as compared with a placebo in patients with gastrointestinal stromal tumor (GIST) refractory 
to standard therapy [75]. Encouraged by these results, a phase II INTEGRATE study was con-
ducted and revealed a significant prolongation of mPFS in favor of regorafenib as compared 
with a placebo [76].
3.4. Resistance to antiangiogenic therapy
In consideration of targeting molecules to suppress angiogenesis, the caveats lie in a para-
doxical increase in tumor growth or in a rebound phenomenon that is greater tumor aggres-
siveness followed by the cessation of antiangiogenic therapy. An animal xenograft model 
exhibited the worrying observation of a higher incidence of metastasis and/or shorter sur-
vival time by antiangiogenic therapy [77], suggesting angiogenesis inhibition as a driving 
force in tumor progression to stages of greater malignancy. It is plausible for cancer cells 
exposed to hypoxic conditions to acquire properties that allow them to overcome the lack 
of energy and oxygen supply. This acquisition means a transformation to a threatening 
form of tumor adaptation against starving strategy, leading to assume a malignant behav-
ior. In addition, the rebound phenomenon should be mentioned because the withdrawal of 
antiVEGF TKI resulted in a rapid regrowth of the tumor vasculature that was suppressed 
during the therapy [78]. For example, renal cell cancer patients showing complete response 
by sunitinib and sorafenib experienced a relapse on discontinuation of the therapy, but 
all responded again to a reintroduction of the drug [79]. These findings have confirmed 
several current limitations to antiangiogenic therapy, posing future challenges for their 
expanded use.
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The precise mechanisms for this phenomenon are unclear. In addition to the multiple path-
ways to escape from the VEGF-VEGFR blockade as described earlier, it is possible that tumor 
hypoxia induced by antiangiogenic therapy triggers another angiogenic switch for cancer cells 
to survive or forces cancer cells to migrate to their nonhypoxic lesion. At present, there is no 
clinical evidence that the rebound phenomenon is a result of anti-angiogenic therapy or any 
adverse effects of the inherent nature of anti-angiogenic therapy. A recent review has proposed 
putative mechanisms of resistance to antiangiogenic therapy [80], which could uncover eva-
sive or intrinsic changes within the tumor as resistance mechanisms of antiangiogenic therapy.
A key molecule involved in another angiogenic switch under conditions of antiangiogenic 
therapy is the hypoxia inducible factor (HIF) [81]. HIF induces a hepatocyte growth factor 
(HGF) [82] that subsequently activates a mesenchymal-epidermal transition factor receptor 
(MET). Activation of this HGF/MET pathway leads to GC cell proliferation, survival, and 
migration [83]; thus, the HIF and HGF/MET axis is another rational therapeutic target for 
overcoming the resistance to antiangiogenic therapy. Furthermore, a strategy of HGF/MET 
inhibition is important because MET solely [84] or its interaction with EGFR [85] or HER3 [86] 
may mediate resistance to anti-HER therapy.
3.5. HGF/MET inhibitors—rilotumumab and onartuzumab
A number of inhibitors of the HGF/MET pathway have been developed, including monoclo-
nal antibodies, such as rilotumumab and onartuzumab, or small molecule RTK inhibitor such 
as foretinib.
Rilotumumab, a humanized monoclonal antibody against HGF, has been investigated by 
two first-line RCTs. RILOMET-1 is a comparison between rilotumumab plus ECX (epirubicin, 
cisplatin and capecitabine) and a placebo plus ECX [87], and RILOMET-2 aims to evaluate 
cisplatin plus capecitabine with or without rilotumumab [88]. A rilotumumab benefit was 
seen in MET-positive patients [89] or was rilotumumab concentration dependent [90]. A very 
recent pharmacokinetic study revealed a lack of drug-drug interaction between rilotumumab 
and ECX [91]; however, the results were negative, thereby recommending the early cessation 
of the RILOMET-1 study [87]. Onartuzumab is a recombinant, fully humanized, monoclonal 
anti-MET antibody. A randomized phase II study of FOLFOX with or without onartuzumab 
failed to gain positive results with regard to mPFS and mOS [92]. Foretinib, an oral small mol-
ecule multikinase inhibitor that targets MET and VEGFR-2, has been evaluated by a phase II 
study; however, the results are discouraging [93].
4. Future perspectives
GC and breast cancer have similarities with regard to HER2 positivity rate and molecularly tar-
geted agents first used, such as trastuzumab. However, differences are apparent with regard to 
tumor response to another HER-inhibitor between the two tumors. The evidence obtained by 
the current clinical trials suggests that GC and breast cancer do not necessarily show the same 
response to the HER-2 targeted therapies even if both tumors are HER2 positive. Such similarities 
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and differences also exist between GC and colorectal cancer. This is partly ascribed to the absence 
of a validated biomarker specific for GC, for which we are currently unable to select patients who 
may benefit most or those who may most likely suffer toxicities. The recruitment of molecularly 
unselected patients may be one reason why many clinical trials did not add benefits or show 
any superiority over the conventional chemotherapy. The molecular categorization according 
to which pathways are most activated and which molecules are predominantly involved, as 
well as which factors or genes are most predictive to response and toxicities highlights the most 
responsible therapeutic target(s) and the opportunity to explore the most cost-effective agents. 
These challenges could enable only molecularly selected patients to be treated and the benefit-
to-toxicity ratio will likely improve as well. This will ultimately allow clinicians to administer the 
right treatment to the right patients. Clinical trials with unselected patients are nearing their end, 
and welcome to those recruiting only correctly selected patients. The innovation of new thera-
peutic agents designed under this concept will certainly emerge in the future to help oncologists 
improve the clinical management of GC.
5. Conclusions
Chemotherapy has reached a plateau of efficacy for GC, with an mOS of around 12 months. 
Unfortunately, progress in treating this disease with chemotherapy over the last years has 
lagged behind other malignancies such as breast and colorectal cancer. During this time, 
molecular targeting therapies for colorectal cancer have evolved and their clinical efficacy 
has been evaluated by various phase III trials, resulting in the mOS being at least doubled. In 
GC, the use of molecularly targeted therapies is still in the early stages, but more and more 
targeted drugs have begun to be developed to target each step of the signaling pathways. 
Disappointingly, however, both monoclonal antibodies and RTK inhibitors targeting signal 
transduction pathways failed to meet expectations or their efficacy was modest at best.
Such a painful slow advance is partly ascribed to either the lack of validated biomarkers to 
predict a therapeutic response or adverse events to molecular targeting therapy or to escape 
or resistance phenomena. Better therapeutic responses could sometimes be obtained at the 
expense of adverse events; however, drug-related severe adverse events might depress 
patient QOL. In addition, the blockade of a single signal transduction axis does not provide 
long-term efficacy due to escape or resistance phenomena. Research should be continued to 
bridge these adverse events and efficacy gaps or to circumvent resistance, but we are still far 
from any major breakthrough. Such a reality is challenging, but thanks to the accumulation 
of the knowledge of the mechanisms of RTK action and its downstream signal transduction 
cascade, there are several candidate surrogate biomarkers of response and adverse events, 
or multiple blockade strategies or kinases are being developed. New predictive biomark-
ers and the clarification of resistance mechanisms may hopefully lead to the selection of a 
potentially drug-sensitive cohort, to intensify drug efficacy, and to predict more accurately 
adverse events, holding promise for more tailored therapies. In this respect, both challenges 
and progress engender optimism as they unveil biological mechanisms underlying GC, ulti-
mately identifying those patients most likely to benefit.
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